OTCMKTS:CYDY - CytoDyn Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.5060 -0.01 (-1.94 %) (As of 02/19/2019 12:16 PM ET)Previous Close$0.5140Today's Range$0.5060 - $0.5352-Week Range$0.0552 - $0.8360Volume504,598 shsAverage Volume336,825 shsMarket Capitalization$149.34 millionP/E Ratio-1.74Dividend YieldN/ABeta0.35 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company is based in Vancouver, Washington. Receive CYDY News and Ratings via Email Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIPN/A Webwww.cytodyn.com Phone360-980-8524Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16Price-To-Earnings Trailing P/E Ratio-1.74 Forward P/E Ratio-2.41 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-8.43Profitability EPS (Most Recent Fiscal Year)($0.29) Net Income$-50,140,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-528.65%Miscellaneous Employees6 Outstanding Shares295,133,000Market Cap$149.34 million OptionableNot Optionable CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions What is CytoDyn's stock symbol? CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY." How were CytoDyn's earnings last quarter? CytoDyn Inc (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. View CytoDyn's Earnings History. When is CytoDyn's next earnings date? CytoDyn is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for CytoDyn. What price target have analysts set for CYDY? 1 brokers have issued 12 month price targets for CytoDyn's shares. Their predictions range from $2.00 to $2.00. On average, they expect CytoDyn's share price to reach $2.00 in the next year. This suggests a possible upside of 288.3% from the stock's current price. View Analyst Price Targets for CytoDyn. What is the consensus analysts' recommendation for CytoDyn? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytoDyn. Has CytoDyn been receiving favorable news coverage? Media headlines about CYDY stock have trended positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CytoDyn earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of CytoDyn's key competitors? Some companies that are related to CytoDyn include Basilea Pharmaceutica (BPMUF), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Assembly Biosciences (ASMB), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), Kura Oncology (KURA), Aurinia Pharmaceuticals (AUPH), Urogen Pharma (URGN), Eidos Therapeutics (EIDX), Akorn (AKRX), Karyopharm Therapeutics (KPTI), Flexion Therapeutics (FLXN), ChemoCentryx (CCXI) and Synthorx (THOR). Who are CytoDyn's key executives? CytoDyn's management team includes the folowing people: Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)Dr. Denis R. Burger, Scientific Consultant (Age 75)Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical OfficerDr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66) How do I buy shares of CytoDyn? Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CytoDyn's stock price today? One share of CYDY stock can currently be purchased for approximately $0.5150. How big of a company is CytoDyn? CytoDyn has a market capitalization of $151.99 million. The biotechnology company earns $-50,140,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. CytoDyn employs 6 workers across the globe. What is CytoDyn's official website? The official website for CytoDyn is http://www.cytodyn.com. How can I contact CytoDyn? CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected] MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 107 (Vote Outperform)Underperform Votes: 110 (Vote Underperform)Total Votes: 217MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: Why is insider trading harmful?